FLUTICASONE PROPIONATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H31F3O5S
Molecular Weight	500.571
Optical Activity	UNSPECIFIED
Defined Stereocenters	9 / 9
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])C[C@H](F)C4=CC(=O)C=C[C@]34C

InChI

InChIKey=WMWTYOKRWGGJOA-CENSZEJFSA-N

InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB00588
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/fluticasone.html

Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the treatment of asthma. Fluticasone proprionate is marketed under several different brand names such as Flonase®. Fluticasone propionate is also available as a combination product of azelastine hydrochloride and fluticasone propionate called Dymista™. Dymista™ is indicated in patients over 12 years old for symptomatic relief of seasonal allergic rhinitis. Fluticasone propionate binds to the glucocorticoid receptor. Unbound corticosteroids cross the membranes of cells such as mast cells and eosinophils, binding with high affinity to glucocorticoid receptors (GR). The results include alteration of transcription and protein synthesis, a decreased release of leukocytic acid hydrolases, reduction in fibroblast proliferation, prevention of macrophage accumulation at inflamed sites, reduction of collagen deposition, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability and subsequent edema, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. In the management of asthma, the glucocorticoid receptor complexes down-regulates proinflammatory mediators such as interleukin-(IL)-1, 3, and 5, and up-regulates anti-inflammatory mediators such as IkappaB [inhibitory molecule for nuclear factor kappaB1], IL-10, and IL-12. The antiinflammatory actions of corticosteroids are also thought to involve inhibition of cytosolic phospholipase A2 (through activation of lipocortin-1 (annexin)) which controls the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Progesterone receptor 61 Target ID: CHEMBL208 Sources: http://www.drugbank.ca/drugs/DB00588	Agonist 2678		1.0 nM [EC50]
Glucocorticoid receptor 172 Target ID: CHEMBL2034 Sources: http://www.drugbank.ca/drugs/DB00588	Agonist 2678		0.7 nM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Corticosteroid-responsive dermatoses 17 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019957s012lbl.pdf	Primary		Approved 8429	CUTIVATE Approved Use CUTIVATE® Ointment is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adult patients. Launch Date 1990

C_max

Value	Dose	Co-administered	Analyte	Population
23364 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12680886	1000 μg single, intravenous dose: 1000 μg route of administration: Intravenous experiment type: SINGLE co-administered:		FLUTICASONE PROPIONATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
14148 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12680886	1000 μg single, intravenous dose: 1000 μg route of administration: Intravenous experiment type: SINGLE co-administered:		FLUTICASONE PROPIONATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
4.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12680886	1000 μg single, intravenous dose: 1000 μg route of administration: Intravenous experiment type: SINGLE co-administered:		FLUTICASONE PROPIONATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
9% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/076633_ORIGINAL%20APPROVAL_PACKAGE.pdf	1 mg single, intravenous dose: 1 mg route of administration: Intravenous experiment type: SINGLE co-administered:		FLUTICASONE PROPIONATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
16 mg single, oral Highest studied dose Dose: 16 mg Route: oral Route: single Dose: 16 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf	healthy, adult Health Status: healthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf
2 mg 2 times / day multiple, intranasal Highest studied dose Dose: 2 mg, 2 times / day Route: intranasal Route: multiple Dose: 2 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf	healthy, adult Health Status: healthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf
80 mg 1 times / day multiple, oral Highest studied dose Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf	healthy, adult Health Status: healthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf
1320 ug 1 times / day multiple, respiratory Highest studied dose Dose: 1320 ug, 1 times / day Route: respiratory Route: multiple Dose: 1320 ug, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20548slr020,20121slr030_flovent_lbl.pdf	healthy, adult Health Status: healthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20548slr020,20121slr030_flovent_lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20548slr020,20121slr030_flovent_lbl.pdf
3520 ug single, respiratory Highest studied dose Dose: 3520 ug Route: respiratory Route: single Dose: 3520 ug Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20548slr020,20121slr030_flovent_lbl.pdf	healthy, adult Health Status: healthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20548slr020,20121slr030_flovent_lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20548slr020,20121slr030_flovent_lbl.pdf
25 ug 2 times / day steady, respiratory Dose: 25 ug, 2 times / day Route: respiratory Route: steady Dose: 25 ug, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02980133	unhealthy, children n = 211 Health Status: unhealthy Condition: Asthma Age Group: children Population Size: 211 Sources: https://clinicaltrials.gov/ct2/show/NCT02980133	Other AEs: Pneumonia mycoplasmal... Other AEs: Pneumonia mycoplasmal (serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT02980133
50 ug 2 times / day steady, respiratory Dose: 50 ug, 2 times / day Route: respiratory Route: steady Dose: 50 ug, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02980133	unhealthy, children n = 208 Health Status: unhealthy Condition: Asthma Age Group: children Population Size: 208 Sources: https://clinicaltrials.gov/ct2/show/NCT02980133	Other AEs: Disruptive mood dysregulation disorder... Other AEs: Disruptive mood dysregulation disorder (serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT02980133
200 ug 1 times / day steady, intranasal Dose: 200 ug, 1 times / day Route: intranasal Route: steady Dose: 200 ug, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01817790	unhealthy n = 314 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Population Size: 314 Sources: https://clinicaltrials.gov/ct2/show/NCT01817790	Other AEs: Thirst, Gastrointestinal viral infection... Other AEs: Thirst (below serious, 1 patient) Gastrointestinal viral infection (below serious, 1 patient) Headache (below serious, 2 patients) Throat irritation (below serious, 1 patient) Palpitations (below serious, 1 patient) Laceration (below serious, 1 patient) Hypertension (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT01817790
880 ug 2 times / day steady, oral Dose: 880 ug, 2 times / day Route: oral Route: steady Dose: 880 ug, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00275561	unhealthy n = 19 Health Status: unhealthy Condition: Eosinophilic Esophagitis Population Size: 19 Sources: https://clinicaltrials.gov/ct2/show/NCT00275561	Other AEs: Esophageal candidiasis... Other AEs: Esophageal candidiasis (below serious, 5 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00275561
880 ug 2 times / day steady, oral Dose: 880 ug, 2 times / day Route: oral Route: steady Dose: 880 ug, 2 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00426283	unhealthy n = 28 Health Status: unhealthy Condition: Eosinophilic Esophagitis Population Size: 28 Sources: https://clinicaltrials.gov/ct2/show/NCT00426283	Other AEs: General system disorders NEC, General system disorders NEC... Other AEs: General system disorders NEC (below serious, 7 patients) General system disorders NEC (below serious, 2 patients) General system disorders NEC (below serious, 1 patient) General system disorders NEC (below serious, 5 patients) General system disorders NEC (below serious, 4 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00426283

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587 substrate 1737	substrate 1037	substrate 1217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP3A5 73	CYP1A1 349 CYP1A2 1054 CYP1B1 92 CYP2A6 543 CYP2B6 664 CYP2C8 693 CYP2C18 138 CYP2C19 991 CYP2E1 667 CYP3A5 395 CYP3A7 110 P-gp 1537	P-gp 257

Drug as perpetrator

Target	Modality	Activity
CYP3A4 1925	inhibitor 3277 Sources: https://pubs.acs.org/doi/abs/10.1021/tx100124k Page: -	weak
CYP3A5 130	inhibitor 3277 Sources: https://pubs.acs.org/doi/abs/10.1021/tx100124k Page: -	yes
P-gp 1650	inducer 1573 Sources: https://www.sciencedirect.com/science/article/pii/S0041008X12001019 Page: -	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A1 349	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
CYP1A2 1054	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
CYP1B1 92	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
CYP2A6 543	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
CYP2B6 664	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
CYP2C18 138	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
CYP2C19 991	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
CYP2C8 693	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
CYP2C9 1037	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
CYP2D6 1217	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
CYP2E1 667	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	no
P-gp 1537	substrate 3367 Sources: https://www.sciencedirect.com/science/article/pii/S0041008X12001019 Page: -	weak
CYP3A5 395	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	yes [Km 3.8 uM]
CYP3A7 110	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16565171/ Page: -	yes [Km 5.2 uM]
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209022Orig1s000ClinPharmR_rev.pdf#page=14 Page: 14.0	yes [Km 5.3 uM]	yes (co-administration study) Comment: Ritonavir A drug interaction trial with fluticasone propionate aqueous nasal spray in healthy subjects has shown that ritonavir (a strong CYP3A4 inhibitor) can significantly increase plasma fluticasone propionate exposure, resulting in significantly reduced serum cortisol concentrations Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209022Orig1s000ClinPharmR_rev.pdf#page=14 Page: 14.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:31441	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31441
ChemicalBook	CB1252206	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1252206
ChemicalBook	CB52622685	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB52622685
ChemicalBook	CB5274961	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5274961
ChemicalBook	CB94798094	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB94798094
MolPort	MolPort-003-847-468	https://www.molport.com/shop/molecule-link/MolPort-003-847-468
Selleck Chemicals	fluticasone-propionate-Flonase-Veramyst	http://www.selleckchem.com/products/fluticasone-propionate-Flonase-Veramyst.html
ZINC	ZINC000003920027	http://zinc15.docking.org/substances/ZINC000003920027
eMolecules	2736271	https://www.emolecules.com/cgi-bin/more?vid=2736271
eMolecules	31226118	https://www.emolecules.com/cgi-bin/more?vid=31226118

PubMed

Title	Date	PubMed
Small airway inflammation in asthma.	2001	11737932
Using clinical measures of disease control to reduce the burden of asthma.	2001	11700792
Inhaled fluticasone propionate for chronic asthma.	2001	11687040
Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma.	2001	11596838
Should inhaled corticosteroids be used in the long term treatment of chronic obstructive pulmonary disease?	2001	11577791
Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options?	2001	11520256
Systemic availability of inhaled budesonide and fluticasone propionate: healthy versus asthmatic lungs.	2001	11520251
Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma.	2001	11511026
Improvement in health care utilization and pulmonary function with fluticasone propionate in patients with steroid-dependent asthma at a National Asthma Referral Center.	2001 Aug	11515977
Effects of single-dose fluticasone on exercise-induced asthma in asthmatic children: a pilot study.	2001 Aug	11477728
A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma.	2001 Aug 15	11530030
Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis.	2001 Aug 4	11485952
Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus babyhaler spacer in the treatment of asthma in preschool-aged children.	2001 Dec	11742910
One-year treatment with different dosing schedules of fluticasone propionate in childhood asthma. Effects on hyperresponsiveness, lung function, and height.	2001 Dec 1	11739137
The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease. Results of the DIMCA program.	2001 Dec 1	11739135
Fluticasone propionate and budesonide do not influence bone metabolism in the long term treatment of asthma.	2001 Jan-Feb	11449531
Fluticasone and salmeterol downregulate in vitro, fibroblast proliferation and ICAM-1 or H-CAM expression.	2001 Jul	11510784
Drugs for the treatment of allergic diseases.	2001 Jul	11488426
Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial.	2001 Jul	11485708
Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate.	2001 Jul	11453895
Effects of intranasal corticosteroids on the hypothalamic-pituitary-adrenal axis in children.	2001 Jul	11449204
Pharmacokinetics of intranasal corticosteroids.	2001 Jul	11449203
A novel pharmacologic action of glucocorticosteroids on leukotriene C4 catabolism.	2001 Jul	11447392
GRbeta expression in nasal polyp inflammatory cells and its relationship to the anti-inflammatory effects of intranasal fluticasone.	2001 Jul	11447383
A comparison of clinical use of fluticasone propionate and beclomethasone dipropionate in pediatric asthma.	2001 Jun	11559968
[Effect of FP inhalation and airway inflammation assessed by ECP in asthma].	2001 Jun	11530386
[Peak inspiratory flow rates attained by asthmatic patients through a dry-powder inhaler of fluticasone propionate].	2001 Jun	11517519
Topical corticosteroids in chronic rhinosinusitis: a randomized, double-blind, placebo-controlled trial using fluticasone propionate aqueous nasal spray.	2001 Jun	11486442
Improved asthma control after changing from low-to-medium doses of other inhaled corticosteroids to low-dose fluticasone propionate.	2001 Jun 8	11549975
Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler.	2001 Nov	11736861
Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients.	2001 Nov	11730179
Effects of 2 inhaled corticosteroids on growth: results of a randomized controlled trial.	2001 Nov	11695935
Novel anti-inflammatory effects of the inhaled corticosteroid fluticasone propionate during lung myofibroblastic differentiation.	2001 Nov 1	11673549
Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis.	2001 Nov 23	11730731
Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis.	2001 Nov 26	11718589
Comparison of the tissue affinity of glucocorticoids to human lung, nasal and skin tissue in vitro.	2001 Oct	11715635
The effect of low-dose inhaled fluticasone propionate on exhaled nitric oxide in asthmatic patients and comparison with oral zafirlukast.	2001 Oct	11686419
Fluticasone propionate aqueous nasal spray in pregnancy rhinitis.	2001 Oct	11678947
[Combination treatment with inhaled corticosteroid/long-acting beta 2-adrenergic bronchodilator in the treatment of asthma].	2001 Oct	11676144
[Japanese guideline for the diagnosis and management of bronchial asthma (1998)--its results and reversion].	2001 Oct	11676124
Serum dehydroepiandrosterone sulfate concentration as an indicator of adrenocortical suppression in asthmatic children treated with inhaled steroids.	2001 Oct	11600561
Response of preschool children with asthma symptoms to fluticasone propionate.	2001 Oct	11590379
A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy.	2001 Sep	11589270
A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate.	2001 Sep	11589253
Improved safety with equivalent asthma control in adults with chronic severe asthma on high-dose fluticasone propionate.	2001 Sep	11555383
The penetration of 0.005% fluticasone propionate ointment in eyelid skin.	2001 Sep	11511836
Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone.	2001 Sep 1	11549529
Intracranial hypertension and nasal fluticasone propionate.	2001 Sep 22	11566840
Quantification of epimeric budesonide and fluticasone propionate in human plasma by liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry.	2001 Sep 25	11587347
Aerosol characterization of nebulized intranasal glucocorticoid formulations.	2001 Summer	11681655

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Dermatitis Cream/Ointment: Apply a thin film to affected area twice a day

Route of Administration: Topical

In Vitro Use Guide

Pretreatment with Fluticasone propionate (10(-11) M to about 10(-7) M, 24 h) inhibited TNF-alpha-induced VCAM-1 mRNA expression in BEAS-2B in a dose-dependent manner

Name

Type

Language

FLUTICASONE PROPIONATE

Official Name

English

FLUTICASONE PROPIONATE [ORANGE BOOK]

Common Name

English

ADVAIR COMPONENT FLUTICASONE PROPIONATE

Brand Name

English

FLUTICASONE PROPIONATE [USP MONOGRAPH]

Common Name

English

CUTIVATE

Brand Name

English

S-FLUOROMETHYL 6.ALPHA., 9.ALPHA.-DIFLUORO-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-17.ALPHA.-PROPIONYLOXYANDROSTA-1,4-DIENE-17.BETA-. CARBOTHIOATE

Common Name

English

FLIXOTIDE

Brand Name

English

FLUTICASONE PROPIONATE [EP MONOGRAPH]

Common Name

English

FLUTICASONE PROPIONATE COMPONENT OF DYMISTA

Common Name

English

ARMONAIR RESPICLICK

Brand Name

English

LIPO-102 COMPONENT FLUTICASONE PROPIONATE

Common Name

English

FLUTICASONE PROPIONATE [JAN]

Common Name

English

FLOVENT

Code

English

CCI18781

Code

English

FLUTICASONE PROPIONATE [USP-RS]

Common Name

English

PF-00241939

Code

English

FLUTICASONE PROPIONATE [MART.]

Common Name

English

AIRDUO RESPICLICK COMPONENT FLUTICASONE PROPIONATE

Brand Name

English

NSC-759889

Code

English

DYMISTA COMPONENT FLUTICASONE PROPIONATE

Common Name

English

FLUTICASONE PROPIONATE [USAN]

Common Name

English

CCI-18781

Code

English

XHANCE

Brand Name

English

ADVAIR HFA COMPONENT FLUTICASONE PROPIONATE

Common Name

English

Fluticasone propionate [WHO-DD]

Common Name

English

ANDROSTA-1,4-DIENE-17-CARBOTHIOIC ACID, 6,9-DIFLUORO-11-HYDROXY-16-METHYL-3-OXO-17-(1-OXOPROPOXY)-, (6.ALPHA.,11.BETA.,16.ALPHA.,17.ALPHA.)-S-(FLUOROMETHYL) ESTER

Common Name

English

FLUTICASONE PROPIONATE COMPONENT OF ADVAIR

Brand Name

English

FLUTICASONE PROPIONATE COMPONENT OF AIRDUO RESPICLICK

Brand Name

English

FLUTICASONE PROPIONATE [MI]

Common Name

English

FLUTICASONE PROPIONATE COMPONENT OF ADVAIR HFA

Common Name

English

FLUTICASONE-17-PROPIONATE

Common Name

English

FLUTICASONE PROPIONATE [VANDF]

Common Name

English

FLONASE

Brand Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

273208